TY - JOUR T1 - Mutational landscape of high-grade B-cell lymphoma with <em>MYC-, BCL2</em> and/or <em>BCL6</em> rearrangements characterized by whole-exome sequencing JF - medRxiv DO - 10.1101/2021.07.13.21260465 SP - 2021.07.13.21260465 AU - Axel Künstner AU - Hanno M. Witte AU - Jörg Riedl AU - Veronica Bernard AU - Stephanie Stölting AU - Hartmut Merz AU - Vito Olschewski AU - Wolfgang Peter AU - Julius Ketzer AU - Yannik Busch AU - Peter Trojok AU - Nikolas von Bubnoff AU - Hauke Busch AU - Alfred C. Feller AU - Niklas Gebauer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/16/2021.07.13.21260465.abstract N2 - High-grade B-cell lymphoma accompanied with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) poses a cytogenetically-defined provisional entity among aggressive B-cell lymphomas that is traditionally associated with unfavorable prognosis.To better understand the mutational and molecular landscape of HGBL-DH/TH we here performed whole-exome sequencing and deep panel next-generation-sequencing (NGS) of 47 clinically annotated cases. Oncogenic drivers, mutational signatures and perturbed pathways were compared with data from follicular lymphoma (FL), diffuse large-B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).We find an accumulation of oncogenic mutations in NOTCH, IL6/JAK/STAT and NFκB signaling pathways and delineate the mutational relationship within the continuum between FL/DLBCL, HGBL-DH/TH and BL. Further, we provide evidence of a molecular divergence between BCL2 and BCL6 rearranged HGBL-DH. Beyond a significant congruency with the C3/EZB DLBCL cluster in BCL2 rearranged cases on an exome-wide level, we observe an enrichment of the SBS6 mutation signature in BCL6 rearranged cases. Differential gene set enrichment and subsequent network propagation analysis according to cytogenetically defined subgroups revealed an impairment of TP53 and MYC pathway signaling in BCL2 rearranged cases, whereas BCL6 rearranged cases lacked this enrichment, but instead exhibited showed impairment of E2F targets. Intriguingly, HGBL-TH displayed intermediate mutational features in all three aspects.This study elucidates a recurrent pattern of mutational events driving FL into MYC-driven BCL2 rearranged HGBL, unveiling the mutational pathogenesis of this provisional entity. Through this refinement of the molecular taxonomy for aggressive, germinal-center derived B-cell lymphomas, this calls into question the current WHO classification system, especially regarding the status of MYC/BCL6 rearranged HGBL.Competing Interest StatementThe authors have declared no competing interest.Funding StatementA.K. and H.B. acknowledge computational support from the OMICS compute cluster at the University of Luebeck. The research was supported by a grant to N.G. by the Stefan-Morsch-Foundation alongside infrastructural support. H.B. acknowledges funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany Excellence Strategy, EXC 22167-390884018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective study was approved by the ethics committee of the University of Luebeck (reference-no 18-356) and conducted in accordance with the declaration of Helsinki. Patients had given written informed consent regarding routine diagnostic and academic assessment of their biopsy specimen including molecular studies at the Reference center for Hematopathology and transfer of their clinical data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data in bam format from WES and panel sequencing have been deposited in the European genome-phenome archive (EGA) under the accession number EGAS00001005420. https://ega-archive.org/ ER -